1.Quality of Care in Inflammatory Bowel Disease.
The Korean Journal of Gastroenterology 2015;65(3):139-144
Since inflammatory bowel disease (IBD) is a chronic and relapsing disorder, maintaining high quality of care plays an important role in the management of patients with IBD. To develop process-based quality indicator set to improve quality of care, the indicator should be based directly on evidence and consensus. Initially, ImproveCareNow group demonstrated quality improvement by learning how to apply quality improvement methods to improve the care of pediatric patients with IBD. The American Gastroenterological Association has developed adult IBD physician performance measures set and Crohn's and Colitis Foundation of America (CCFA) has developed a set of ten most highly rated process and outcome measures. Recently, The Emerging Practice in IBD Collaborative (EPIC) group generated defining quality indicators for best-practice management of IBD in Canada. Quality of Care through the Patient's Eyes (QUOTE-IBD) was developed as a questionnaire to measure quality of care through the eyes of patients with IBD, and it is widely used in European countries. The current concept of quality of care as well as quality indicator will be discussed in this article.
Humans
;
Inflammatory Bowel Diseases/*diagnosis/pathology/therapy
;
Practice Guidelines as Topic
;
*Quality Indicators, Health Care
;
Surveys and Questionnaires
2.Advances in macrophage-targeting nanoparticles for the diagnosis and treatment of inflammatory bowel disease.
Journal of Zhejiang University. Medical sciences 2023;52(6):785-794
The pathogenesis of inflammatory bowel disease (IBD) is not fully elucidated. However, it has been considered that inflammatory macrophages may be involved in the imbalance of the intestinal mucosal immunity to regulate several signaling pathways, leading to IBD progression. The ratio of M1 to M2 subtypes of activated macrophages tends to increase in the inflamed intestinal section. There are challenges in the diagnosis and treatment of IBD, such as unsatisfactory specificity of imaging findings, low drug accumulation in the intestinal lesions, unstable therapeutic efficacy, and drug-related systemic toxicity. Recently developed nanoparticles may provide a new approach for the diagnosis and treatment of IBD. Nanoparticles targeted to macrophages can be used as contrast agents to improve the imaging quality or used as a drug delivery vector to increase the therapeutic efficiency of IBD. This article reviews the research progress on macrophage-targeting nanoparticles for the diagnosis and treatment of IBD to provide a reference for further research and clinical application.
Humans
;
Inflammatory Bowel Diseases/therapy*
;
Intestines
;
Macrophages/metabolism*
;
Intestinal Mucosa/pathology*
;
Nanoparticles
3.Parenteral Nutritional Support in Gastrointestinal and Liver Diseases.
The Korean Journal of Gastroenterology 2015;65(6):346-353
Protein-calorie malnutrition and deficiencies of specific nutrients could commonly occur in various types of gastrointestinal diseases. These nutritional problems could delay recovery from diseases, resulting in increased morbidity and mortality, and impairment of quality of life. Parenteral nutrition (PN) is one of the methods of nutritional support through which macronutrients (glucose, amino acids, and triglycerides), micronutrients (vitamins and trace elements), water, and electrolytes are administered via peripheral or central venous route. PN could play an important role for patients for whom enteral/oral feeding is contraindicated or cannot meet the patients' requirement for adequate nutrition due to anatomical and/or functional problems. Since insufficient and excessive PN supplement could both be harmful for patients, it is very important to adhere to correct indication, optimal timing, and dosage/composition of PN. In this article, the current role of PN for various gastrointestinal diseases will be reviewed and discussed.
Gastrointestinal Diseases/*pathology/therapy
;
Humans
;
Inflammatory Bowel Diseases/pathology/therapy
;
Liver Diseases/*pathology/therapy
;
Malnutrition/*prevention & control
;
Nutrition Therapy
;
Nutritional Support
;
*Parenteral Nutrition
4.A Case of Intestinal Behcet's Disease Similar to Crohn's Colitis.
Eun Sun KIM ; Woo Chul CHUNG ; Kang Moon LEE ; Bo In LEE ; Hwang CHOI ; Sok Won HAN ; Kyu Yong CHOI ; In Sik CHUNG
Journal of Korean Medical Science 2007;22(5):918-922
Behcet's disease is a multi-systemic vasculitis and characterized by systemic organ involvement. Although the gastrointestinal and systemic features of Behcet's disease and inflammatory bowel disease overlap to a considerable extent, they are generally viewed as two distinct diseases. A 39-yr-old female was diagnosed as having Behcet's disease. She was admitted to our hospital because of oral and genital ulcer, lower abdominal pain, and frequent diarrhea. Colonosopy showed diffuse involvement of multiple longitudinal ulcers with inflammatory pseudopolyps with a cobblestone appearance and ano-rectal fistula was suspected. These findings are extremely rare in Behcet's disease. However, there were no granulomas, the hallmark of Crohn's colitis. Microscopically, perivasculitis and multiple lymph follicles compatible with Behcet's disease were seen. Although being rarely encountered, multiple longitudinal ulcers, cobblestone appearance, and ano-rectal fistula can develop in Behcet's disease, as in Crohn's colitis. Therefore, Behcet's disease and Crohn's disease may be closely related and part of a spectrum of disease.
Adult
;
Behcet Syndrome/diagnosis/*therapy
;
Colitis
;
Colonoscopy
;
Crohn Disease/diagnosis/*therapy
;
Female
;
Humans
;
Inflammation
;
Inflammatory Bowel Diseases/pathology
;
Intestinal Diseases/diagnosis/*therapy
;
Perineum/pathology
;
Ulcer
;
Vulva/pathology
5.Inflammatory bowel disease in children: clinical, endoscopic, radiologic and histopathologic investigation.
Jeong Kee SEO ; Kyung Mo YEON ; Je Geun CHI
Journal of Korean Medical Science 1992;7(3):221-235
This paper reviews our five years' clinical experience (1987 to 1991) of 22 patients with inflammatory bowel disease (IBD). There were 12 patients with Crohn's disease and 10 patients with ulcerative colitis. The mean age at diagnosis was 8.7 years (2 to 14 years). Clinical impressions before referral were chronic diarrhea in 11, irritable bowel syndrome in 5, colon polyp in 4, lymphoma in 3, intestinal tuberculosis in 2, amoebic colitis in 2, ulcerative colitis in 2 children and other diseases. The mean interval from the onset of symptoms to the diagnosis of IBD was 18 months. Diagnosis of Crohn's disease was delayed for more than 13 months in 8 (67%), whereas that of ulcerative colitis was delayed for more than 13 months in 4 (40%). Diarrhea (50%), abdominal pain (36%) and rectal bleeding (36%) were the three most frequent presenting complaints of IBD. Moderately severe abdominal pain was a more common chief complaint in Crohn's disease (58%) than in ulcerative colitis (10%). Hematochezia (90% vs 17%) and moderately severe diarrhea (90% vs 75%) were more common gastrointestinal manifestations in ulcerative colitis than in Crohn's disease. The associated extraintestinal manifestations were oral ulcer in 7, arthralgia in 11 and arthritis in 4, skin lesions in 2, eye lesions in 2 and growth failure in 9 patients. Of 12 children with Crohn's disease, granuloma was found in 5, aphthous ulcerations in 8, cobble stone appearance in 8, skip area or asymmetric lesions in 6, transmural involvement in 7, and perianal fistula in 3. Among 10 children with ulcerative Colitis, there were crypt abscess in 8, granularity or friability in 10 and rectosigmoid ulcerations with purulent exudate in 8 children. The main sites of involvement in children with Crohn's disease were both the small and large bowels in 7 (58%), small bowel only in 2 (16%), and colon only in 3 (25%). Terminal ileum involvement was seen in 75% of Crohn's disease cases. The main sites of involvement in children with ulcerative colitis were total colon in 4 (40%), up to the splenic flexure in 2 (20%), rectosigmoid in 3 (30%) and rectum only in one (10%). Medical treatment including sulfasalazine, and systemic or topical steroid was administered initially in most patients. Seven of 12 patients with Crohn's disease and 2 of 10 patients with ulcerative colitis were operated on.(ABSTRACT TRUNCATED AT 400 WORDS)
Adolescent
;
Child
;
Child, Preschool
;
Colonoscopy
;
Female
;
Follow-Up Studies
;
Humans
;
Incidence
;
*Inflammatory Bowel Diseases/epidemiology/pathology/physiopathology/therapy
;
Korea/epidemiology
;
Male
;
Recurrence
6.Atypical clinical manifestations of amebic colitis.
Jung Hwan YOON ; Ji Gon RYU ; Jong Kyun LEE ; Sae Jin YOON ; Hyun Chae JUNG ; In Sung SONG ; Kyoo Wan CHOI ; Chung Yong KIM
Journal of Korean Medical Science 1991;6(3):260-266
Amebic colitis is a disease revealing diverse clinical manifestations and endoscopic gross features and often confused with other types of colitis. In case of misdiagnosis as an idiopathic inflammatory bowel disease or delayed recognition of intestinal amebiasis, an undesirable outcome may occur resulting from erroneous administration of steroids or delayed antiamebic treatment. To demonstrate the pitfalls in the diagnosis and treatment of intestinal amebiasis, 3 cases of amebic colitis with atypical clinical manifestations are presented in this paper. In conclusion, despite the low sensitivities of routine stool examination for parasite and histopathologic confirmation in biopsy specimen, every effort must be made to find amebic trophozoites either in fresh stool or biopsy specimens for prompt and correct diagnosis of amebic colitis when we manage patients with chronic intestinal ulcerations, even though their clinical course and endoscopic findings are not typical of amebiasis. Moreover, following initial successful anti-amebic therapy, more careful clinical, endoscopical, and parasitological follow-up should be done for the early detection of recurrence.
Adult
;
Aged
;
Aged, 80 and over
;
Colitis, Ulcerative/diagnosis
;
Diagnosis, Differential
;
Diarrhea/etiology
;
Dysentery, Amebic/complications/drug therapy/*pathology
;
Female
;
Humans
;
Inflammatory Bowel Diseases/diagnosis
;
Male
;
Middle Aged
7.Excerpt from the 2022 American Association for the Study of Liver Diseases clinical practice guideline: management of primary sclerosing cholangitis and cholangiocarcinoma.
Chinese Journal of Hepatology 2023;31(1):35-41
What are the new contents of the guideline since 2010?A.Patients with primary and non-primary sclerosing cholangitis (PSC) are included in these guidelines for the diagnosis and management of cholangiocarcinoma.B.Define "related stricture" as any biliary or hepatic duct stricture accompanied by the signs or symptoms of obstructive cholestasis and/or bacterial cholangitis.C.Patients who have had an inconclusive report from MRI and cholangiopancreatography should be reexamined by high-quality MRI/cholangiopancreatography for diagnostic purposes. Endoscopic retrograde cholangiopancreatography should be avoided for the diagnosis of PSC.D. Patients with PSC and unknown inflammatory bowel disease (IBD) should undergo diagnostic colonoscopic histological sampling, with follow-up examination every five years until IBD is detected.E. PSC patients with IBD should begin colon cancer monitoring at 15 years of age.F. Individual incidence rates should be interpreted with caution when using the new clinical risk tool for PSC for risk stratification.G. All patients with PSC should be considered for clinical trials; however, if ursodeoxycholic acid (13-23 mg/kg/day) is well tolerated and after 12 months of treatment, alkaline phosphatase (γ- Glutamyltransferase in children) and/or symptoms are significantly improved, it can be considered to continue to be used.H. Endoscopic retrograde cholangiopancreatography with cholangiocytology brushing and fluorescence in situ hybridization analysis should be performed on all patients suspected of having hilar or distal cholangiocarcinoma.I.Patients with PSC and recurrent cholangitis are now included in the new unified network organ sharing policy for the end-stage liver disease model standard.J. Liver transplantation is recommended after neoadjuvant therapy for patients with unresectable hilar cholangiocarcinoma with diameter < 3 cm or combined with PSC and no intrahepatic (extrahepatic) metastases.
Child
;
Humans
;
Cholangitis, Sclerosing/diagnosis*
;
Constriction, Pathologic/complications*
;
In Situ Hybridization, Fluorescence
;
Cholangiocarcinoma/therapy*
;
Liver Diseases/complications*
;
Cholestasis
;
Inflammatory Bowel Diseases/therapy*
;
Bile Ducts, Intrahepatic/pathology*
;
Bile Duct Neoplasms/therapy*
8.Changing Paradigm in the Management of Inflammatory Bowel Disease.
The Korean Journal of Gastroenterology 2015;65(5):268-272
Inflammatory bowel disease (IBD) is a chronic progressive idiopathic inflammatory disorder that involves the digestive tract from the mouth to the anus. Over the past decades, many therapeutic strategies have been developed to manage IBD, but therapeutic strategies based only on relief of clinical symptoms have not changed the natural history of this disease entity. This underlines the importance of understanding the natural history of IBD itself. When we look at the natural history of Crohn's disease (CD), it first begins with inflammation of the intestinal mucosa and this inflammatory reaction proceeds to stenosing or penetrating reaction if not adequately controlled. However, it takes a considerable amount of time before mucosal inflammation proceeds to stenosis of the intestinal lumen or penetration into the adjacent bowel. Therefore, it can be expected that if proper care is given during that period, progression of CD to such a complicated disease could be prevented. Even though the concept of mucosal healing was introduced in the early 1990s, no correlation could be observed between healing of mucosal lesions and relief of clinical symptoms. However, the introduction of biologic agents targeting tumor necrosis factor has changed the way to treat IBD that is refractory to standard medications and has allowed us to aim for a new therapeutic goal, 'deep remission'. Further advances in biologic agents have provided highly effective treatments for IBD, making deep remission a realistic goal. Whether IBD patients may benefit by experiencing a 'deep' remission beyond the control of clinical symptoms need to be evaluated in further investigation. Nevertheless, it can be anticipated that attaining deep remission might ultimately have an impact on important outcomes such as the need for surgery and the quality of life.
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
;
Antibodies, Monoclonal/therapeutic use
;
Colitis, Ulcerative/drug therapy/metabolism/pathology
;
Crohn Disease/drug therapy/metabolism/pathology
;
Humans
;
Inflammatory Bowel Diseases/drug therapy/metabolism/*pathology
;
Intestinal Mucosa/metabolism/pathology
;
Mesalamine/therapeutic use
;
Tumor Necrosis Factor-alpha/immunology/metabolism
9.Treatment of inflammatory bowel disease with Chinese drugs administered by both oral intake and retention enema.
Xiao-hua LING ; Xin YU ; De-jun KONG ; Cheng-yi HU ; Yu HONG ; Xiao-ming YANG
Chinese journal of integrative medicine 2010;16(3):222-228
OBJECTIVETo study the clinical effect of Chinese drugs administered by both oral intake and retention enema on inflammatory bowel diseases (IBD).
METHODSAdopting a randomized controlled design, 78 patients were assigned to three groups: 26 patients in group A treated with Chinese drugs given by both oral intake and retention enema, 27 in group B with Chinese drugs given by retention enema only, and 25 in group C with given Western medicine. The changes before and after a 30-day treatment of the patients' symptoms (including diarrhea, abdominal pain, mucous or pus-bloody stool), colonoscopic examination scores and histopathology of the colonic membrane were observed.
RESULTSGroup A showed the best outcomes in all the aspects of clinical comprehensive effectiveness. Improvements in the main symptoms, colonoscopic scores and histopathology of the colonic membrane were significantly different from those in groups B and C, respectively (P<0.05). Meanwhile comparisons between groups B and C showed insignificant differences (P>0.05); group B was better in ameliorating tenesmus (P<0.05).
CONCLUSIONThrough the use of Chinese drugs administered by both oral intake and retention enema to treat IBD, which combined external-internal therapies for both overall regulation and local management, it was confirmed that the Chinese medicine could embody the therapeutic principle of attending to both disease-diagnosis and syndrome-differentiation.
Administration, Oral ; Adult ; Colon ; drug effects ; pathology ; Colonoscopy ; Drugs, Chinese Herbal ; administration & dosage ; pharmacology ; therapeutic use ; Enema ; Humans ; Inflammatory Bowel Diseases ; drug therapy ; pathology ; Middle Aged ; Treatment Outcome ; Young Adult
10.The Intestinal Microbiota and Human Disease.
The Korean Journal of Gastroenterology 2013;62(2):85-91
Advances in sequencing technology and the development of metagenomics have opened up new ways to investigate the microorganisms inhabiting the human gut. The intestinal microbiota confer protection against pathogens, contribute to the maturation of the immune system, and regulate host metabolism. The composition of gut microbiota in early life is influenced by mode of birth, diet, and antibiotics. Decreased biodiversity and alterations in the composition of the intestinal microbiota have been observed in many diseases including obesity, neonatal necrotizing enterocolitis, inflammatory bowel disease, and recurrent Clostridium difficile infection. Therapeutic options for the diseases linked to imbalance in the microbiota include modifying the gut microbiota through diet, probiotics, and fecal transplants.
Animals
;
Anti-Bacterial Agents/therapeutic use
;
Clostridium difficile/isolation & purification/pathogenicity
;
Enterocolitis, Pseudomembranous/drug therapy/microbiology/pathology
;
Fatty Liver/etiology/microbiology
;
Humans
;
Inflammatory Bowel Diseases/etiology/microbiology
;
Intestines/*microbiology
;
*Microbiota
;
Obesity/etiology/microbiology